Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPROMPT: Ceftriaxone, Clarithromycin, and Metronidazole vs Standard of Care for PPROM
NCT06396078Phase 4Recruiting
- Sponsor
- The Ohio State University
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ceftriaxone, clarithromycin and metronidazole in preterm premature rupture of membranes (pPROM) (2 arms), sponsored by The Ohio State University. Primary endpoint: Latency. Started Jul 2024; status: recruiting.
02
Drugs
ceftriaxoneclarithromycinmetronidazole
03
Conditions
preterm premature rupture of membranes (pPROM)
Beyond the preview
Go deeper on NCT06396078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06396078.